Company profile: Allorion Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule therapeutics for cancer and autoimmune diseases, including an EGFR L858R allosteric inhibitor program to enhance existing treatments and prevent resistance; ARTS-021, an oral CDK2 inhibitor in Phase I/II for advanced/metastatic solid tumors; ARTS-011, a selective TYK2 inhibitor in early development; and high-throughput phenotypic screening to identify Werner Helicase inhibitors.
Products and services
- ARTS-021: Advances a clinical-stage, potent orally administered CDK2 inhibitor in Phase I/II, treating advanced or metastatic solid tumors via CDK2 inhibition
- EGFR L858R Allosteric Inhibitor Program: Engineers allosteric inhibitors targeting EGFR L858R mutations to enhance efficacy of existing treatments and prevent resistance
- ARTS-011: Progresses a preclinical-stage, potent and selective TYK2 inhibitor for treating inflammatory diseases, with early development activities underway
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Allorion Therapeutics
ImmunoMet Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology products for cancer patients, including Lixumistat (IM156), an orally bioavailable small molecule inhibitor of Protein Complex 1 that targets Oxidative Phosphorylation to reduce aberrant cell growth in cancer and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoMet Therapeutics company profile →
Juno Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies for the treatment of cancer, formed through a unique partnership with Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute to advance a broad pipeline of breakthrough immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Juno Therapeutics company profile →
SciBase
HQ: Sweden
Website
- Description: Provider of medical devices leveraging Electrical Impedance Spectroscopy (EIS) to detect malignant melanoma and assess skin barrier function. Products include Nevisense, a point-of-care platform using EIS and AI for non-invasive melanoma detection and objective clinical decision-making, and Nevisense Go, a portable EIS device for detailed skin barrier assessment in research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SciBase company profile →
Abingdon Health
HQ: United Kingdom
Website
- Description: Provider of rapid and near-patient medical diagnostic testing solutions as an innovative, technology-led company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abingdon Health company profile →
Lumicell
HQ: United States
Website
- Description: Provider of image-guided cancer surgery solutions, including the Lumicell Direct Visualization System (DVS), a fluorescence-guided imaging system that detects residual cancerous tissue in real time during lumpectomy, and LUMISIGHT (pegulicianine), an optical imaging agent used with DVS to highlight cancerous tissue during lumpectomy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumicell company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Allorion Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Allorion Therapeutics
2.2 - Growth funds investing in similar companies to Allorion Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Allorion Therapeutics
4.2 - Public trading comparable groups for Allorion Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →